Child malnutrition is a pressing public health concern, particularly among those under 5
years old, affecting physical, mental, and motor development, leading to chronic issues
in adulthood and future generations. A report by UNICEF, WHO, and the World Bank (March
2020) emphasized the alarming global malnutrition rates, with 144.0 million children
under 5 experiencing malnutrition, including stunting (47.0 million) and severe
malnutrition (14.3 million). Lower-middle-income countries bear the brunt, with
two-thirds of stunted and three-quarters of wasted children worldwide. In Vietnam (2020
data), 19.5% of children under 5 are stunted, 11.6% underweight, and 4.7% wasted. In
parallel, constipation is a rising health issue in Asia and worldwide, affecting children
even in developed economies. Functional constipation is prevalent in children (12-28%).
In Vietnam, 24.6% of 3-5-year-olds face constipation, peaking at 54.9% between 36 and 48
months. Untreated constipation poses severe physical, psychological, and socioeconomic
complications, such as gastrointestinal inflammation, anorexia, and nutrient
malabsorption. Anorexia, prevalent in children, affects their nutrient absorption,
growth, and height. Anorexic children have 2.5-3 times higher risks of underweight
malnutrition and stunting. Children suffering from malnutrition and digestive disorders
face impaired enzyme production, nutrient loss, and gut dysbiosis, causing slow weight
gain. Malnourished children with lower immunity become more ill-prone, exacerbating
anorexia and forming a problematic cycle. In recent years, the role of probiotics in
human health and disease has attracted the attention of researchers. This may be partly
due to the excellent activity of probiotics in preventing and alleviating illness.
Currently, research on probiotics mainly focuses on treating gastrointestinal diseases
with some traditional probiotics. However, a problem arises when adding these
microorganisms can hardly survive in extremely harsh environments. Therefore,
spore-forming probiotics have attracted the interest of researchers. The viability and
stability of these bacteria are significantly better when compared to other probiotics
due to their spore-forming ability. Among Bacillus species, Bacillus clausii, Bacillus
subtilis, and Bacillus coagulans are bacteria that can form spores stable in the acidic
environment of gastric juice and, therefore, pass through the stomach safely and also
produce digestive enzymes such as amylase and protease in the intestine. B. coagulans is
the only Bacillus species that can produce lactic acid, which reduces the pH, bringing
the environment to a slightly acidic status. This is an excellent environmental condition
for beneficial intestinal bacteria to grow and prevent the growth of harmful bacteria. At
the same time, it enhances absorption and improves anorexia and constipation in children.
Previous studies also have demonstrated that probiotics can significantly reduce stool
retention time in the intestines and improve stool consistency. Based on the research
results above, spore probiotics can be considered natural and safe agents to relieve
constipation, anorexia, and slow weight gain in children. To substantiate this argument,
the investigators plan to conduct a clinical trial titled "Evaluating the effectiveness
of the LiveSpo® Preg-Mom and LiveSpo® KIDS spore probiotics in supporting the reduction
of constipation, anorexia, and slow weight gain in children aged 24-60 months".
The overall aim of this study is to assess the efficacy of two types of probiotics, the
first one containing 3 billion spores of three bacterial species, Bacillus subtilis, B.
clausii, and B. coagulans spores (LiveSpo® Preg-Mom) per ampoule and the second one
having 3 billion spores of two bacterial species per ampoule (LiveSpo® KIDS), including
Bacillus subtilis, and B. clausii, in supporting the treatment of children with
constipation, anorexia, and slow weight gain.
The first objective is to evaluate the effectiveness of these products in alleviating
typical symptoms of constipation, anorexia, and slow weight gain. The secondary aim is
measuring changes in typical cytokines in the blood, in IgA indices in stool, and
microbiota composition in stool before and after supplemental usages of with LiveSpo®
Preg-Mom and LiveSpo® KIDS.
For this aim, the study is designed as a randomized, double-blind, and controlled
clinical trial with 201 participants diagnosed with constipation, anorexia, and slow
weight gain. The participants are randomized into 3 groups using permuted block
randomization: a control group using RO water (CC), experimental group 1 using LiveSpo®
Preg-Mom (AA), and experimental group 2 using LiveSpo® KIDS (BB). Each patient receives 2
ampoules of the assigned probiotic product daily, divided into 2 doses daily. The study
includes clinical assessment of indicators at days 0, 7, and 28, such as weight, types of
stool, frequency of daily bowel movements, and average eating time per meal.
Contents and Methods for sub-clinical detection. The study participants are children aged
24 to 60 months who are diagnosed with constipation, anorexia, and slow weight gain.
Hematology and biochemical tests are conducted on days 0 and 28 at MEDLATEC (proper
noun) hospital, Vietnam.
A real-time PCR assay is conducted on stool samples at days 0, 7, and 28 at the
Spobiotic Research Center (proper noun) to detect probiotic spores, including B.
subtilis, B. clausii, and B. coagulans, to cross-check the appropriate usage of
probiotics or placebo in the experimental and control groups, respectively.
ELISA tests are conducted at days 0, 7, and 28 at the Spobiotic Research Center
(proper noun) to determine pro-inflammatory/ anti-inflammatory cytokine levels in
blood samples and IgA levels in stool samples, respectively, for evaluating changes
in immune-related indicators during the supportive treatment.
The tests indicating ratios of bacteria Gr (+) and Gr (-) in stool samples are
conducted at days 0, 7, and 28 at MEDLATEC (proper noun) hospital, in order to:
evaluate the change in the balance between the types of bacteria Gr (+) and Gr (-)
bacteria in gut.
The 16S V3-V4 metagenome sequencing analysis is carried out at Macrogen (Seoul,
Korea) using next-generation sequencing (NGS) technology on the Illumina MiSeq
platform (Illumina, San Diego, CA, USA), utilizing a 2 × 250 bp run configuration.
DNA samples extracted from stool samples of about 10 representative patients from
each group on day 0 and day 28 are used for the analysis, to identify changes in the
microbiome.
Data collection and statistical analysis involve the collection of individual
medical records and systematizing patient information into a dataset.
The tabular analysis is performed on dichotomous variables using the χ2 test or Fisher's
exact test when the expected value of any cell is below five. Continuous variables are
compared using the Wilcoxon test, t-test, or the Mann-Whitney test when data are not
normally distributed. To determine if there is a statistically significant difference
between the three groups, an ANOVA test is performed. Spearman's correlation analysis
assesses the correlations among the variables. Statistical and graphical analyses are
performed on GraphPad Prism v8.4.3 software (GraphPad Software, CA, USA). The
significance level of all analyses is set at p < 0.05. P-values. The efficacy of LiveSpo®
Preg-Mom and LiveSpo® KIDS is evaluated and compared to the control based on the
following clinical and sub-clinical criteria obtained from the Experiment and Control
groups: Primary outcome is: (i) Symptomatic relief of constipation, anorexia, and slow
weight gain; Secondary outcomes are: (ii) Regulated levels of pro-inflammatory cytokines
such as IL-6, IL-10, IL-17, IL-23 and TNF-alpha in blood samples. (iii) Regulated IgA
levels in fecal samples. (iv) Improved diversity and count of beneficial bacterial
species compared to harmful bacteria in the gut microbiota.